Introduction: The objective of this study was to determine the impact of intra-ab-
| INTRODUC TI ON
Epithelial ovarian cancer (EOC) is the leading cause of death from gynecological malignancies. Approximately 70% women with EOC present with Federation of Gynecology and Obstetrics (FIGO) stages III-IV with a 5-year overall survival (OS) of below 25%. 1 The standard treatment is primary debulking surgery and adjuvant platinum-based chemotherapy. Several studies have demonstrated that the presence of no postoperative intra-abdominal residual disease is associated with a significant increase in OS. [2] [3] [4] Complete cytoreductive surgery is considered a key part in the management of advanced EOC. Women are selected for primary debulking surgery based on their Eastern Cooperative Oncology Group performance status (PS), their age, and the location of the disease, which is evaluated using CT, PET-CT or MRI, and discussed in a multidisciplinary conference. Women in whom achieving no residual disease is considered impossible may be treated with neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS).
A similar OS has been observed in EOC groups randomized for neoadjuvant chemotherapy followed by interval debulking surgery and in primary debulking surgery followed by adjuvant chemotherapy in women with stage IIIC-IV EOC.
5
Most studies have examined the prognostic impact of residual disease among women with EOC diagnosed at stage III disease.
Studies conducted on the prognostic impact of intra-abdominal residual disease in stage IV EOC show there is an increase in OS if
residual disease = 0 is obtained, but large prospective populationbased studies are missing. [6] [7] [8] [9] [10] [11] [12] In the period 2013-2016 71% of women with stage IIIC-IV disease who underwent primary debulking surgery in Denmark obtained residual disease = 0. 1 To date no diagnostic tool that predicts the level of cytoreduction with certainty exists. Studies have shown that a superior prognosis is associated with residual disease ≤1 cm compared with residual disease >1 cm. 3, 4 However, knowledge of other prognostic factors related to the presence of residual disease is needed.
The objective of this nationwide prospective study was to investigate the impact of residual disease size by comparing women with stage IV and stage IIIB-IIIC EOC who underwent primary debulking surgery. The secondary objective was to determine whether the residual disease type (carcinomatosis vs tumor mass, vs both) and location (upper vs lower abdominal, vs both) had an impact on OS.
| MATERIAL AND ME THODS
The women were identified through the national clinical Danish
Gynecological Cancer Database, which contains prospectively collected data on more than 97% of all Danish women with gynecological cancer since January 2005. The exposure variables were defined as follows:
1.
Residual disease size. The women were divided into five groups according to residual disease size: (1) = 0, (2) ≤1 cm, (3) >1 cm and ≤2 cm, (4) >2 cm, and (5) not available (NA). Residual disease defined the extent of intra-abdominal macroscopic visible disease after primary debulking surgery.
Residual disease type.
Women with residual disease were divided into four groups according to their intra-abdominal residual disease type: (1) residual tumor mass only, (2) residual carcinomatosis only, (3) both residual tumor mass and residual carcinomatosis, and (4) NA.
Location of residual disease.
Women with residual disease were divided in to four groups according to the location of their intra-abdominal residual disease: (1) upper abdominal, (2) lower abdominal, (3) both upper and lower abdominal, and (4) NA.
| Statistical analyses
Descriptive statistics were used to describe the population. The association between clinicopathological parameters and residual disease were assessed using chi-squared tests. The association
Key message
This study sought to determine the impact of residual disease on overall survival in women with stage IV epithelial ovarian cancer undergoing primary debulking surgery. We conclude that achieving no or ≤1 cm residual disease increases overall survival.
between subgroups on residual disease size, type, and location was assessed using Mann-Whitney U test and chi-squared tests. Univariate survival analyses were performed using the 
| Ethical approval
According to Danish law, no ethical approval was necessary for this database research project. Data protection authority approval was obtained (no. 2012-58-0004 dated 1 April 2017).
| RE SULTS
We identified 3824 women who underwent primary debulking sur- Multivariate Cox analyses confirmed a significant survival benefit for residual disease = 0 compared with women with residual disease, regardless of size (Figure 2) . The benefit was significant in women with both stage IIIB-IIIC and stage IV when adjusted for their age, PS, histology, and ascites (0 mL vs < 500 mL vs > 500 mL) (Table 3) .
Age, PS, and histology had significant impact on OS in both analyses.
Ascites (Table 4 ).
An overview of all FIGO stages according to residual disease is provided in Table S1 . Surgical outcome and surgeries performed are described in Table S2 and Table S3 .
| D ISCUSS I ON
In this prospective nationwide study we found that residual disease size is an independent prognostic factor in stage IIIB-IIIC and stage IV EOC, and that women in stage IV do benefit from primary de- [Color figure can be viewed at wileyonlinelibrary.com] to achieve. Our data support this hypothesis, as 78.5% of the 966 women referred to neoadjuvant chemotherapy, and thus excluded in the present study, were diagnosed in or later than 2010.
During the same period, the treatment of ovarian cancer was centralized in four gynecological and oncological centers in Denmark associated with higher rates of residual disease = 0, lower rates of primary debulking surgery and increased OS in women with stage IIIC and IV ovarian cancer. 16 In our study, the rate of women achieving residual disease = 0 at primary debulking surgery increased from It is debated whether neoadjuvant chemotherapy followed by interval debulking surgery is a better strategy for women with stage IV disease. In two randomized, controlled trials women with stage IIIC-IV EOC were randomized to either primary debulking surgery or neoadjuvant chemotherapy followed by interval debulking surgery, independently of their disease status. The study reported there was a higher rate of residual disease = 0 in women receiving neoadjuvant chemotherapy followed by interval debulking surgery compared with primary debulking surgery; however, no difference in OS was observed between the groups independent of their residual disease status. failed to show a significant difference in OS between those receiving primary debulking surgery and those receiving neoadjuvant chemotherapy followed by interval debulking surgery, independent of their residual disease status. 5 Overall, residual disease = 0 was reported to have the highest impact on survival in women undergoing primary debulking surgery. However, a benefit in OS may be achieved in a group who are referred to neoadjuvant chemotherapy followed by interval debulking surgery specifically because achieving residual disease = 0 or residual disease ≤1 cm at primary debulking surgery is considered impossible. The studies also show that primary debulking surgery is associated with higher rates of postoperative adverse effects and lower quality of life scores than neoadjuvant chemotherapy followed by interval debulking surgery. 5, 25, 26 Thus, to reduce the risk of postoperative complications, improve the quality of life and possibly also OS, neoadjuvant chemotherapy followed by interval debulking surgery might be a better alternative for women in whom residual disease = 0 or residual disease ≤1 cm cannot be expected.
The extent to which the improved survival is related to residual disease = 0 is in fact a reflection of tumor biology is a matter of continual discussion. Our results demonstrate that the tumor biology cannot be the only factor determining surgical outcome and prognosis.
The rate of complete macroscopic resection has increased in women undergoing primary debulking surgery, while the benefit in OS of achieving residual disease = 0 is consistent, thereby improving the OS in the total population with EOC. Should surgical outcome and prognosis be determined by tumor biology alone, higher rates of residual disease = 0 would have no influence on OS. However, tumor biology may influence the surgeon's ability to achieve residual disease = 0.
Ovarian cancer is known to be very heterogeneous, depending on the histological subtype, with great differences in prognosis, response to chemotherapy, and patterns of spread. 27 Furthermore, increases in the tumor grade correlate with poorer prognosis. 28 Indeed, we found that residual disease = 0 was obtained in 61.9% and 44.8% of women with low-grade and high-grade serous histology, respectively, suggesting that achieving residual disease = 0 may be associated with the histological subtype. Regarding oncological treatment, it has been found that clear cell and mucinous adenocarcinomas especially have low chemo sensitivity, and omitting primary debulking surgery in these groups will take a toll on survival.
29
Tumor biology could also be a plausible explanation for the dif- Our results demonstrated a poor OS in women with both residual carcinomatosis and residual tumor mass and in women with residual disease located in both the upper and lower abdomen. In our opinion, these groups represent a selection of women with a significantly higher postoperative tumor burden and could reflect that high postoperative tumor burden has a negative impact on OS.
To our knowledge no standardized method of assessing postoperative tumor burden exists, as surgeons normally describe residual disease size, defined by the diameter of the largest single cancer element, and therefore not the total tumor burden. A method that uses a more detailed description of the postoperative tumor burden than that used in the present study is needed to confirm that it has a negative impact on OS.
The present study has several strengths. It is based on nationwide, prospectively collected data, which represents an unselected group of women with ovarian cancer in Denmark, minimizing selection bias. In addition, our survival analyses are powerful, with 99.5%
life-long follow up.
Our study also has certain limitations. First, incomplete registration may occur. This may decrease the power of the study, but the database is large and as it collects data prospectively it is unlikely to influence the direction of the estimates. Second, re-evaluations of pathological diagnoses and staging were not performed, result- 
| CON CLUS ION
Our results confirm the impact of residual disease on OS in women with stage IV as well as stages IIIB-IIIC EOC undergoing primary debulking surgery. Women achieving residual disease = 0 had the largest survival benefit. Our results demonstrate that primary debulking surgery is the right approach in a subgroup of stage IV EOC women, where residual disease = 0 can be achieved. The selection of the appropriate women with stage IV for primary debulking surgery as opposed to neoadjuvant chemotherapy followed by interval debulking surgery is crucial, and a validated diagnostic tool to predict the ability to achieve residual disease = 0 is greatly needed.
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